董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarit Firon | 女 | Independent Director | 59 | 未披露 | 1.83 | 2026-03-26 |
| Adrian Percy | 男 | Independent Director | 60 | 未披露 | 1.06 | 2026-03-26 |
| Dan Falk | 男 | Independent Director | 81 | 未披露 | 0.73 | 2026-03-26 |
| Ofer Haviv | 男 | Director,President and Chief Executive Officer | 60 | 46.80万美元 | 8.90 | 2026-03-26 |
| Leon Y. Recanati | 男 | Independent Director | 78 | 未披露 | 9.42 | 2026-03-26 |
| Nir Nimrodi | 男 | Chairperson of the Board and Independent Director | 57 | 未披露 | 1.85 | 2026-03-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Polina Ravzin | 女 | VP Finance | 44 | 未披露 | 未持股 | 2026-03-26 |
| Gabi Tarcic | 男 | Vice President Product | 46 | 24.10万美元 | 1.50 | 2026-03-26 |
| Ilia Zhidkov | 男 | Vice President Computational Platform | 49 | 未披露 | 3.13 | 2026-03-26 |
| Yaron Eldad | 男 | Chief Financial Officer | 60 | 29.20万美元 | 3.66 | 2026-03-26 |
| Ofer Haviv | 男 | Director,President and Chief Executive Officer | 60 | 46.80万美元 | 8.90 | 2026-03-26 |
董事简历
中英对照 | 中文 | 英文- Sarit Firon
-
Sarit Firon自2014年6月起担任本公司的董事会成员。自2012年12月起，Firon女士曾担任Extreme Reality Ltd.的首席执行官，这是一家使用单一标准摄像头提供实时的基于软件的3D动作捕捉技术的公司。2011年11月至2012年11月，Firon女士在Kenshoo Ltd.担任财务总监。2007年11月至2011年10月，Firon女士在MediaMind担任首席财务官。 Firon女士此前还担任过P-Cube（被Cisco Systems收购）的首席财务官，还担任Radcom Ltd.（一家在纳斯达克股票市场上市的公司）的首席财务官。 Firon女士还担任Datorama Ltd.（一家数据分析工具的开发商）的董事会成员。2000年至2006 年，Firon女士担任MetaLink Ltd.（在纳斯达克股票交易市场上市的一家有线和无线宽带通信解决方案开发商）的审计委员会的外部董事和成员。 Firon女士持有以色列Tel-Aviv University会计学和经济学的学士学位。
Sarit Firon has served as a director of Evogene Ltd. since Augt 2016, and as chairperson from Augt 2021 to March 2025. Ms. Firon is a managing partner of Team8 Group and a co founder and managing partner of Team8 Capital, the investment arm of Team8 Group, which invests in early stage technology startups. Ms. Firon serves on several boards of directors of Team8 Capital portfolio. Ms. Firon has served as a director for several public and private companies, including Ivix since 2021, Classiq Technologies since 2020, FundGuard since 2020, Spiral since 2019, and Perion Network Ltd. (Nasdaq: PERI) from November 2016 until June 2022. Ms. Firon previoly served as a director of SetSail Technologies from 2019 to 2024. Since Augt 2020, she has served as a board member of Friends of the izmann Institute. Ms. Firon holds a B.A. in Accounting and Economics from Tel Aviv University, Israel. - Sarit Firon自2014年6月起担任本公司的董事会成员。自2012年12月起，Firon女士曾担任Extreme Reality Ltd.的首席执行官，这是一家使用单一标准摄像头提供实时的基于软件的3D动作捕捉技术的公司。2011年11月至2012年11月，Firon女士在Kenshoo Ltd.担任财务总监。2007年11月至2011年10月，Firon女士在MediaMind担任首席财务官。 Firon女士此前还担任过P-Cube（被Cisco Systems收购）的首席财务官，还担任Radcom Ltd.（一家在纳斯达克股票市场上市的公司）的首席财务官。 Firon女士还担任Datorama Ltd.（一家数据分析工具的开发商）的董事会成员。2000年至2006 年，Firon女士担任MetaLink Ltd.（在纳斯达克股票交易市场上市的一家有线和无线宽带通信解决方案开发商）的审计委员会的外部董事和成员。 Firon女士持有以色列Tel-Aviv University会计学和经济学的学士学位。
- Sarit Firon has served as a director of Evogene Ltd. since Augt 2016, and as chairperson from Augt 2021 to March 2025. Ms. Firon is a managing partner of Team8 Group and a co founder and managing partner of Team8 Capital, the investment arm of Team8 Group, which invests in early stage technology startups. Ms. Firon serves on several boards of directors of Team8 Capital portfolio. Ms. Firon has served as a director for several public and private companies, including Ivix since 2021, Classiq Technologies since 2020, FundGuard since 2020, Spiral since 2019, and Perion Network Ltd. (Nasdaq: PERI) from November 2016 until June 2022. Ms. Firon previoly served as a director of SetSail Technologies from 2019 to 2024. Since Augt 2020, she has served as a board member of Friends of the izmann Institute. Ms. Firon holds a B.A. in Accounting and Economics from Tel Aviv University, Israel.
- Adrian Percy
-
Adrian Percy自2019年2月起担任公司董事。Percy博士在Biolumic，Hifidelity Genetics，Agrosavfe，Agplenus我们的子公司和Enkochem的董事会任职。他是Terramera公司、Zasso公司、Agrimetis公司和Rothamsted Research公司的科技董事会成员。Percy博士目前担任Finistere Ventures的首席技术官，并经常通过他自己的咨询公司Nomad Technology Consulting担任公司的农业顾问或独立董事。此前，Percy博士曾担任拜耳公司作物科学部的研究与开发主管，作为其执行委员会的一部分。任职Bayer公司16年期间，他也曾领导Bayer公司的北美作物保护开发活动，以及作物科学整个部门的监管事务活动。Percy博士曾在法国、德国和美国的Rhone Poulenc、Aventis CropScience和Bayer的研究与开发部门任职。Percy博士在利物浦大学（University of Liverpool）获得药理学学士学位，在伯明翰大学（University of Birmingham）获得毒理学硕士学位和生物化学博士学位。
Adrian Percy has served as a director of Evogene Ltd. since February 2019. Dr. Percy has served on the board of directors of AgPlen Ltd. since April 2023, BioLumic Ltd. since April 2019, Nufarm Ltd. since June 2023, and FungiAlert Inc. since March 2022. He is a member of the science and technology boards of Harpe BioHerbicide Solutions Inc., and Biotalys NV. Dr. Percy is serving as the Executive Director of the N.C. Plant Sciences Initiative and is a Professor in the Department of Plant and Microbial Biology at North Carolina State University since 2021. Dr. Percy is currently a venture partner with DYDX Capital and frequently acts as an advisor to companies through his own consultancy company, Nomad Technology Consulting. From 2019 2021, Dr. Percy served as Chief Technology Officer at UPL Ltd. From 2014 2018, he served as the head of research and development for the Crop Science division of Bayer as part of its executive committee. During his 16 year tenure at Bayer, he also led regulatory affairs activities across the entire division of Crop Science beten 2013 and 2014 and crop protection development activities for Bayer in North America beten 2011 and 2013. Dr. Percy has held positions in the research and development departments of Aventis CropScience SA beten 2000 and 2002, Rhone Poulenc SA beten 1996 and 2000, and Bayer in France, Germany and the United States. Dr. Percy holds a bachelor's degree in pharmacology from the University of Liverpool, England, as ll as a master's degree in toxicology and a doctorate in biochemistry from the University of Birmingham, England. - Adrian Percy自2019年2月起担任公司董事。Percy博士在Biolumic，Hifidelity Genetics，Agrosavfe，Agplenus我们的子公司和Enkochem的董事会任职。他是Terramera公司、Zasso公司、Agrimetis公司和Rothamsted Research公司的科技董事会成员。Percy博士目前担任Finistere Ventures的首席技术官，并经常通过他自己的咨询公司Nomad Technology Consulting担任公司的农业顾问或独立董事。此前，Percy博士曾担任拜耳公司作物科学部的研究与开发主管，作为其执行委员会的一部分。任职Bayer公司16年期间，他也曾领导Bayer公司的北美作物保护开发活动，以及作物科学整个部门的监管事务活动。Percy博士曾在法国、德国和美国的Rhone Poulenc、Aventis CropScience和Bayer的研究与开发部门任职。Percy博士在利物浦大学（University of Liverpool）获得药理学学士学位，在伯明翰大学（University of Birmingham）获得毒理学硕士学位和生物化学博士学位。
- Adrian Percy has served as a director of Evogene Ltd. since February 2019. Dr. Percy has served on the board of directors of AgPlen Ltd. since April 2023, BioLumic Ltd. since April 2019, Nufarm Ltd. since June 2023, and FungiAlert Inc. since March 2022. He is a member of the science and technology boards of Harpe BioHerbicide Solutions Inc., and Biotalys NV. Dr. Percy is serving as the Executive Director of the N.C. Plant Sciences Initiative and is a Professor in the Department of Plant and Microbial Biology at North Carolina State University since 2021. Dr. Percy is currently a venture partner with DYDX Capital and frequently acts as an advisor to companies through his own consultancy company, Nomad Technology Consulting. From 2019 2021, Dr. Percy served as Chief Technology Officer at UPL Ltd. From 2014 2018, he served as the head of research and development for the Crop Science division of Bayer as part of its executive committee. During his 16 year tenure at Bayer, he also led regulatory affairs activities across the entire division of Crop Science beten 2013 and 2014 and crop protection development activities for Bayer in North America beten 2011 and 2013. Dr. Percy has held positions in the research and development departments of Aventis CropScience SA beten 2000 and 2002, Rhone Poulenc SA beten 1996 and 2000, and Bayer in France, Germany and the United States. Dr. Percy holds a bachelor's degree in pharmacology from the University of Liverpool, England, as ll as a master's degree in toxicology and a doctorate in biochemistry from the University of Birmingham, England.
- Dan Falk
-
Dan Falk， 是3家以色列（Israel）纳斯达克（Nasdaq）上市的公司：Nice Systems有限公司“Nice”、Attunity 有限公司和Nova的董事会成员；以及是Ormat Technologies的一位董事会成员。他还是一家在Frankfurt证券交易所上市的以色列（Israel）公司- Orad Hi-Tec Systems有限公司的董事长。1999年7月-2000年11月期间，曾在一家荷属安的列斯群岛公司- Sapiens国际公司的总裁和首席运营官。1995年8月-1999年7月期间，曾是该公司的副执行总裁；1994年6月-1995年8月期间，担任该公司的副执行总裁和财务总监。在此之前，他曾于1992年10月-1994年6月期间，担任该公司的副总裁和财务总监。1985年一直到合并的完成之前，担任Orbot的财务总管和财务总监。他是于1973年从Hebrew大学商学院获得他的工商管理硕士学位的。拥有15年的金融、银行业务经验，包括在加入Orbot之前，在Discount Bank担任数个高级职位。
Dan Falk has been a member of Ormat Technologies, Inc. since November 2004 and Lead Independent Director since August 2020. From 2001 to 2004 Mr. Falk was a business consultant to several public and private companies. From 1999 to 2000 Mr. Falk was Chief Operating Officer and Chief Executive Officer of Sapiens International N.V. From 1995 to 1999 Mr. Falk was an Executive Vice President of Orbotech Ltd. From 1985 to 1995 Mr. Falk was Vice President of Finance and Chief Financial Officer at Orbot Systems Ltd. and Orbotech Ltd. Mr. Falk also serves as a member of the board of directors of Nice Systems Ltd., a NASDAQ-listed company. During the past five years, Mr. Falk served as a member of the board of directors of the following public companies, for which he no longer serves as a director: Attunity Ltd., Orbotech Ltd., Advanced Vision Technology AVT Ltd. and Orad Hi Tech Systems Ltd. Mr. Falk received a BA in Economics and Political Science from Hebrew University in 1968 and an MBA from Hebrew University in 1972. - Dan Falk， 是3家以色列（Israel）纳斯达克（Nasdaq）上市的公司：Nice Systems有限公司“Nice”、Attunity 有限公司和Nova的董事会成员；以及是Ormat Technologies的一位董事会成员。他还是一家在Frankfurt证券交易所上市的以色列（Israel）公司- Orad Hi-Tec Systems有限公司的董事长。1999年7月-2000年11月期间，曾在一家荷属安的列斯群岛公司- Sapiens国际公司的总裁和首席运营官。1995年8月-1999年7月期间，曾是该公司的副执行总裁；1994年6月-1995年8月期间，担任该公司的副执行总裁和财务总监。在此之前，他曾于1992年10月-1994年6月期间，担任该公司的副总裁和财务总监。1985年一直到合并的完成之前，担任Orbot的财务总管和财务总监。他是于1973年从Hebrew大学商学院获得他的工商管理硕士学位的。拥有15年的金融、银行业务经验，包括在加入Orbot之前，在Discount Bank担任数个高级职位。
- Dan Falk has been a member of Ormat Technologies, Inc. since November 2004 and Lead Independent Director since August 2020. From 2001 to 2004 Mr. Falk was a business consultant to several public and private companies. From 1999 to 2000 Mr. Falk was Chief Operating Officer and Chief Executive Officer of Sapiens International N.V. From 1995 to 1999 Mr. Falk was an Executive Vice President of Orbotech Ltd. From 1985 to 1995 Mr. Falk was Vice President of Finance and Chief Financial Officer at Orbot Systems Ltd. and Orbotech Ltd. Mr. Falk also serves as a member of the board of directors of Nice Systems Ltd., a NASDAQ-listed company. During the past five years, Mr. Falk served as a member of the board of directors of the following public companies, for which he no longer serves as a director: Attunity Ltd., Orbotech Ltd., Advanced Vision Technology AVT Ltd. and Orad Hi Tech Systems Ltd. Mr. Falk received a BA in Economics and Political Science from Hebrew University in 1968 and an MBA from Hebrew University in 1972.
- Ofer Haviv
-
Ofer Haviv 自2002年1月，他加入本公司并担任财务总监。自2004年12月起，他担任公司的总裁兼首席执行官。2006年和2012年，他分别担任了两家子公司（Evogene公司和Evofuel有限公司）的董事局主席。 2006年至2007年，他担任本公司总裁。 他是一位注册会计师，并持有特拉维夫大学会计和经济学学士学位。
Ofer Haviv has served as Evogene's President and Chief Executive Officer since December 2004 after having joined the company in January 2002 as Chief Financial Officer. Mr. Haviv serves as Chairman of the Board of Directors of our subsidiaries. From 2006 to 2007 Mr. Haviv served as a director of the company. Mr. Haviv is a Certified Public Accountant and holds a BA in Accounting and Economics from Tel Aviv University. - Ofer Haviv 自2002年1月，他加入本公司并担任财务总监。自2004年12月起，他担任公司的总裁兼首席执行官。2006年和2012年，他分别担任了两家子公司（Evogene公司和Evofuel有限公司）的董事局主席。 2006年至2007年，他担任本公司总裁。 他是一位注册会计师，并持有特拉维夫大学会计和经济学学士学位。
- Ofer Haviv has served as Evogene's President and Chief Executive Officer since December 2004 after having joined the company in January 2002 as Chief Financial Officer. Mr. Haviv serves as Chairman of the Board of Directors of our subsidiaries. From 2006 to 2007 Mr. Haviv served as a director of the company. Mr. Haviv is a Certified Public Accountant and holds a BA in Accounting and Economics from Tel Aviv University.
- Leon Y. Recanati
-
Leon Y. Recanati 自2005年5月起担任公司董事。Recanati 先生自2003年起担任 GlenRock Israel Ltd. 的董事长兼首席执行官。此前，Recanati 先生曾担任 IDB Holding Corporation、Clal Industries Ltd.、Azorim Investment Development and Construction Co Ltd.、Delek Israel Fuel Corporation 以及 Super-Sol Ltd. 的首席执行官和/或董事长。他还创立了 Clal Biotechnologies Industries Ltd.，这是一家在以色列运营的生物技术投资公司。Recanati 先生拥有 Hebrew University of Jerusalem 工商管理硕士学位。
Leon Y. Recanati has served as a director of company since May 2005. Mr. Recanati has served as chairman and chief executive officer of GlenRock Israel Ltd. since 2003. Previously, Mr. Recanati was chief executive officer and/or chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an M.B.A. - Leon Y. Recanati 自2005年5月起担任公司董事。Recanati 先生自2003年起担任 GlenRock Israel Ltd. 的董事长兼首席执行官。此前，Recanati 先生曾担任 IDB Holding Corporation、Clal Industries Ltd.、Azorim Investment Development and Construction Co Ltd.、Delek Israel Fuel Corporation 以及 Super-Sol Ltd. 的首席执行官和/或董事长。他还创立了 Clal Biotechnologies Industries Ltd.，这是一家在以色列运营的生物技术投资公司。Recanati 先生拥有 Hebrew University of Jerusalem 工商管理硕士学位。
- Leon Y. Recanati has served as a director of company since May 2005. Mr. Recanati has served as chairman and chief executive officer of GlenRock Israel Ltd. since 2003. Previously, Mr. Recanati was chief executive officer and/or chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an M.B.A.
- Nir Nimrodi
-
Nir Nimrodi，曾在Odysight.Ai Inc.服役。自2023年8月起担任Ai Inc.的董事。他在生命科学、制药和生物技术行业的初创企业和大型全球企业拥有超过25年的工作经验。从2019年5月到2024年11月，他担任Accellix Inc.（生命科学公司）的董事长兼首席执行官。2014年至2019年4月，他担任Intrexon（现为Precigen， Inc.）的首席商务官。在此之前，他曾担任Life Technologies Inc.（现为Thermo Fisher的一部分）的多个执行职务，并曾担任Proneuron Biotechnologies Inc.和Mindsense Biosystems Ltd.的首席执行官。此外，他目前担任Evogene Ltd.（纳斯达克股票代码：EVGN）和私人公司Genesee Scientific和Scopio Labs的董事会成员。他持有特拉维夫大学（Tel-Aviv University）经济学学士学位和工商管理硕士学位。
Nir Nimrodi Nir Nimrodi has served on board of directors since Augt 2023. Mr. Nimrodi has over 25 years' experience working in start ups and large global binesses in the life sciences, pharmaceutical, and biotechnology indtries. From May 2019 to November 2024, Mr. Nimrodi was the chairman and chief executive officer of Accellix Inc., a life sciences company. From 2014 to April 2019, Mr. Nimrodi was the chief biness officer of Intrexon (currently Precigen, Inc.). Prior to this, he held several executive roles at Life Technologies Inc. (now part of Thermo Fisher), and was chief executive officer at Proneuron Biotechnologies Inc. and Mindsense Biosystems Ltd. In addition, Mr. Nimrodi currently serves as chairman of the board of Evogene Ltd. (NASDAQ: EVGN) and a member of the board of the private companies MNDL Bio and Scopio Labs. From July 2022 to December 2024, Mr. Nimrodi served as a member of the board of Genesee Scientific. Mr. Nimrodi holds a B.A. in Economics and an MBA from Tel Aviv University. - Nir Nimrodi，曾在Odysight.Ai Inc.服役。自2023年8月起担任Ai Inc.的董事。他在生命科学、制药和生物技术行业的初创企业和大型全球企业拥有超过25年的工作经验。从2019年5月到2024年11月，他担任Accellix Inc.（生命科学公司）的董事长兼首席执行官。2014年至2019年4月，他担任Intrexon（现为Precigen， Inc.）的首席商务官。在此之前，他曾担任Life Technologies Inc.（现为Thermo Fisher的一部分）的多个执行职务，并曾担任Proneuron Biotechnologies Inc.和Mindsense Biosystems Ltd.的首席执行官。此外，他目前担任Evogene Ltd.（纳斯达克股票代码：EVGN）和私人公司Genesee Scientific和Scopio Labs的董事会成员。他持有特拉维夫大学（Tel-Aviv University）经济学学士学位和工商管理硕士学位。
- Nir Nimrodi Nir Nimrodi has served on board of directors since Augt 2023. Mr. Nimrodi has over 25 years' experience working in start ups and large global binesses in the life sciences, pharmaceutical, and biotechnology indtries. From May 2019 to November 2024, Mr. Nimrodi was the chairman and chief executive officer of Accellix Inc., a life sciences company. From 2014 to April 2019, Mr. Nimrodi was the chief biness officer of Intrexon (currently Precigen, Inc.). Prior to this, he held several executive roles at Life Technologies Inc. (now part of Thermo Fisher), and was chief executive officer at Proneuron Biotechnologies Inc. and Mindsense Biosystems Ltd. In addition, Mr. Nimrodi currently serves as chairman of the board of Evogene Ltd. (NASDAQ: EVGN) and a member of the board of the private companies MNDL Bio and Scopio Labs. From July 2022 to December 2024, Mr. Nimrodi served as a member of the board of Genesee Scientific. Mr. Nimrodi holds a B.A. in Economics and an MBA from Tel Aviv University.
高管简历
中英对照 | 中文 | 英文- Polina Ravzin
Polina Ravzin自2022年2月起担任Evogene财务副总裁。Eldad先生受聘后，Ravzin女士承担其首席财务官职责。在加入公司之前，Ravzin女士曾在DSIT Solutions Ltd.和橡子能源 Inc.（纳斯达克/OTCQB：ACFN）担任财务总监兼首席财务官助理。Ravzin女士拥有特拉维夫大学会计和经济学学士学位，是以色列的注册会计师。
Polina Ravzin has served as VP Finance of Evogene since February 2022. Upon Mr. Eldad's conclion of employment, Ms. Ravzin shall assume his responsibilities as Chief Financial Officer. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc. (Nasdaq/OTCQB: ACFN). Ms. Ravzin holds a B.A. in Accounting and Economics from Tel Aviv University, and is a Certified Public Accountant in Israel.- Polina Ravzin自2022年2月起担任Evogene财务副总裁。Eldad先生受聘后，Ravzin女士承担其首席财务官职责。在加入公司之前，Ravzin女士曾在DSIT Solutions Ltd.和橡子能源 Inc.（纳斯达克/OTCQB：ACFN）担任财务总监兼首席财务官助理。Ravzin女士拥有特拉维夫大学会计和经济学学士学位，是以色列的注册会计师。
- Polina Ravzin has served as VP Finance of Evogene since February 2022. Upon Mr. Eldad's conclion of employment, Ms. Ravzin shall assume his responsibilities as Chief Financial Officer. Prior to joining the Company, Ms. Ravzin served as controller and assistant to the CFO at DSIT Solutions Ltd. and Acorn Energy Inc. (Nasdaq/OTCQB: ACFN). Ms. Ravzin holds a B.A. in Accounting and Economics from Tel Aviv University, and is a Certified Public Accountant in Israel.
- Gabi Tarcic
Gabi Tarcic于2026年1月被任命为Evogene的首席开发官。Tarcic博士在研发项目和作为生物技术行业的高级主管方面拥有丰富的经验。在加入Evogene之前，Tarcic博士曾在Fore Biotherapeutics（前身为NovellDx Israel）担任过多个职位，最近一次是在2019年1月至2024年12月期间担任其首席技术官。他还在2024年1月至2024年9月期间担任Baobab Therapeutics IL Ltd.的首席技术官。Tarcic博士拥有以色列伊兹曼科学研究所生物学博士学位和生物学硕士学位。
Gabi Tarcic was appointed as Evogene's Chief Development Officer in January 2026. Dr. Tarcic has extensive experience in research and development projects and as a senior executive in the biotech industry. Prior to joining Evogene, Dr. Tarcic has served in vario positions at Fore Biotherapeutics (formerly NovellDx Israel), most recently as its Chief Technology Officer from January 2019 to December 2024. He also served as the Chief Technology Officer at Baobab Therapeutics IL Ltd. from January 2024 to September 2024. Dr. Tarcic holds a Ph.D. in biology and a M.Sc. in biology from The izmann Institute of Science, Israel.- Gabi Tarcic于2026年1月被任命为Evogene的首席开发官。Tarcic博士在研发项目和作为生物技术行业的高级主管方面拥有丰富的经验。在加入Evogene之前，Tarcic博士曾在Fore Biotherapeutics（前身为NovellDx Israel）担任过多个职位，最近一次是在2019年1月至2024年12月期间担任其首席技术官。他还在2024年1月至2024年9月期间担任Baobab Therapeutics IL Ltd.的首席技术官。Tarcic博士拥有以色列伊兹曼科学研究所生物学博士学位和生物学硕士学位。
- Gabi Tarcic was appointed as Evogene's Chief Development Officer in January 2026. Dr. Tarcic has extensive experience in research and development projects and as a senior executive in the biotech industry. Prior to joining Evogene, Dr. Tarcic has served in vario positions at Fore Biotherapeutics (formerly NovellDx Israel), most recently as its Chief Technology Officer from January 2019 to December 2024. He also served as the Chief Technology Officer at Baobab Therapeutics IL Ltd. from January 2024 to September 2024. Dr. Tarcic holds a Ph.D. in biology and a M.Sc. in biology from The izmann Institute of Science, Israel.
- Ilia Zhidkov
Ilia Zhidkov于2026年1月被任命为Evogene的首席技术官。Zhidkov博士于2011年加入Evogene，担任计算基因组学部门的生物信息学家，多年来在公司担任过多个管理职位。Zhidkov博士拥有本古里安大学的遗传学博士学位。
Ilia Zhidkov was appointed as Evogene's Chief Technology Officer in January 2026. Dr. Zhidkov joined Evogene in 2011 as a Bioinformatician in the Computational Genomics Department and has held vario managerial positions in the company over the years. Dr. Zhidkov holds a Ph.D. in Genetics from Ben Gurion University.- Ilia Zhidkov于2026年1月被任命为Evogene的首席技术官。Zhidkov博士于2011年加入Evogene，担任计算基因组学部门的生物信息学家，多年来在公司担任过多个管理职位。Zhidkov博士拥有本古里安大学的遗传学博士学位。
- Ilia Zhidkov was appointed as Evogene's Chief Technology Officer in January 2026. Dr. Zhidkov joined Evogene in 2011 as a Bioinformatician in the Computational Genomics Department and has held vario managerial positions in the company over the years. Dr. Zhidkov holds a Ph.D. in Genetics from Ben Gurion University.
- Yaron Eldad
Yaron Eldad自2022年4月起担任Evogene首席财务官。Eldad先生将于2026年3月底结束在公司的工作。Eldad先生在过去25年中一直在公共和私营技术和生物技术公司担任vario首席财务官职务，包括Yamba Group Int。2011-2021年的RECOLY NV，2008-2010年的RECOLY NV，1998-2007年的E SIM Ltd.。Eldad先生还担任B.O.S. Better Online Solutions Ltd.董事会成员以及审计和薪酬委员会主席。Eldad先生拥有以色列内盖夫本古里安大学经济学和会计学学士学位、以色列杰拉勒姆希伯来大学战略管理高级工商管理硕士学位以及以色列巴伊兰大学法学硕士学位。
Yaron Eldad has served as Chief Financial Officer of Evogene since April 2022. Mr. Eldad will conclude his employment at the Company at the end of March 2026. Mr. Eldad has held vario chief financial officer positions over the last 25 years in public and private technology and biotechnology companies, including Yamba Group Int. Ltd. from 2011 to 2021, Recoly NV from 2008 to 2010, and e Sim Ltd. from 1998 to 2007. Mr. Eldad also serves on the board of directors and as chairman of the audit and compensation committees of B.O.S. Better Online Solutions Ltd. Mr. Eldad holds a B.A. in Economics and Accounting from the Ben Gurion University of the Negev, Israel, an Executive MBA in Strategic Management from the Hebrew University of Jeralem, Israel, and an M.A. in law from the Bar Ilan University, Israel.- Yaron Eldad自2022年4月起担任Evogene首席财务官。Eldad先生将于2026年3月底结束在公司的工作。Eldad先生在过去25年中一直在公共和私营技术和生物技术公司担任vario首席财务官职务，包括Yamba Group Int。2011-2021年的RECOLY NV，2008-2010年的RECOLY NV，1998-2007年的E SIM Ltd.。Eldad先生还担任B.O.S. Better Online Solutions Ltd.董事会成员以及审计和薪酬委员会主席。Eldad先生拥有以色列内盖夫本古里安大学经济学和会计学学士学位、以色列杰拉勒姆希伯来大学战略管理高级工商管理硕士学位以及以色列巴伊兰大学法学硕士学位。
- Yaron Eldad has served as Chief Financial Officer of Evogene since April 2022. Mr. Eldad will conclude his employment at the Company at the end of March 2026. Mr. Eldad has held vario chief financial officer positions over the last 25 years in public and private technology and biotechnology companies, including Yamba Group Int. Ltd. from 2011 to 2021, Recoly NV from 2008 to 2010, and e Sim Ltd. from 1998 to 2007. Mr. Eldad also serves on the board of directors and as chairman of the audit and compensation committees of B.O.S. Better Online Solutions Ltd. Mr. Eldad holds a B.A. in Economics and Accounting from the Ben Gurion University of the Negev, Israel, an Executive MBA in Strategic Management from the Hebrew University of Jeralem, Israel, and an M.A. in law from the Bar Ilan University, Israel.
- Ofer Haviv
Ofer Haviv 自2002年1月，他加入本公司并担任财务总监。自2004年12月起，他担任公司的总裁兼首席执行官。2006年和2012年，他分别担任了两家子公司（Evogene公司和Evofuel有限公司）的董事局主席。 2006年至2007年，他担任本公司总裁。 他是一位注册会计师，并持有特拉维夫大学会计和经济学学士学位。
Ofer Haviv has served as Evogene's President and Chief Executive Officer since December 2004 after having joined the company in January 2002 as Chief Financial Officer. Mr. Haviv serves as Chairman of the Board of Directors of our subsidiaries. From 2006 to 2007 Mr. Haviv served as a director of the company. Mr. Haviv is a Certified Public Accountant and holds a BA in Accounting and Economics from Tel Aviv University.- Ofer Haviv 自2002年1月，他加入本公司并担任财务总监。自2004年12月起，他担任公司的总裁兼首席执行官。2006年和2012年，他分别担任了两家子公司（Evogene公司和Evofuel有限公司）的董事局主席。 2006年至2007年，他担任本公司总裁。 他是一位注册会计师，并持有特拉维夫大学会计和经济学学士学位。
- Ofer Haviv has served as Evogene's President and Chief Executive Officer since December 2004 after having joined the company in January 2002 as Chief Financial Officer. Mr. Haviv serves as Chairman of the Board of Directors of our subsidiaries. From 2006 to 2007 Mr. Haviv served as a director of the company. Mr. Haviv is a Certified Public Accountant and holds a BA in Accounting and Economics from Tel Aviv University.